Royalty Report: Drugs, Pharmaceuticals, Diagnostic Substances – Collection: 26039


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Drugs
  • Pharmaceuticals
  • Diagnostic Substances
  • Diagnostic
  • Biotechnology

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 26039

License Grant
The Licensor grants us rights to various U.S. and international patents and patent applications relating to binding ligands for certain receptors in the brain that are or may be useful as dopamine neuron imaging agents.
License Property
Dopascan and certain related precursors and analogues are covered by U.S. patents that expire in 2009, as well as certain related international patents and patent applications.

Dopascan Injection (“Dopascan”) is a product candidate that is intended to measure dopamine transporter binding to diagnose and monitor the degree of Parkinson’s disease, a disease that affects more than one million patients in the United States. Dopascan is administered to patients intravenously and allows an attending physician to obtain images and measure the density of dopamine transporters in the patient’s brain, which are highly concentrated in a specialized area of the brain and which are significantly decreased in patients with Parkinson’s disease.

IPSCIO Record ID: 26820

License Grant
The Licensor  hereby grants to Licensee subject to the terms and conditions hereof, in the Territory and in the Field (a) an exclusive commercial license under Patent Rights, and (b) a license to use Biological Materials.
License Property
The following comprise Patent Rights U.S. Provisional Application Serial No. 60/141,540, filed June 28, 1999 entitled 'Imaging the Dopamine Transporter to Determine AD-HD'.

We are a development stage biotechnology company engaged in the research and development of biopharmaceutical products for the diagnosis and treatment of central nervous system diseases and for the treatment of some cancers and autoimmune diseases.

Field of Use
Field of use is the Detection and Treatment of Attention Deficit Hyperactivity Disorder.

IPSCIO Record ID: 4453

License Grant
In 2001, Licensor had entered into a distribution and option agreement with the third party, whereby the third party agreed to market and distribute Permaxtm (pergolide mesylate) in the United States.  

In February 2004, the Licensor, further amended their contractual arrangements subject to the sale by a third party (original Licensee)of certain of its assets, including its rights to Zelapar and Permax, to the (current)Licensee. On 25 February 2004, third party’s sale of assets to Licensee closed and the amendments became effective.

License Property
Permax is used for the treatment of Parkinson’s disease and Zelapar is a fast melt formulation of selegiline for the treatment of Parkinson’s disease.  Permax has been approved for marketing in the US as an adjunctive treatment for Parkinson’s disease, a neurological disease characterized by a deficiency of dopamine, a neurotransmitter, in the brain. Permax is one of a class of drugs known as dopamine agonists, which mimic the action of dopamine at certain receptor sites in the brain. Stimulating these receptor sites can reduce the symptoms of Parkinson’s disease, such as tremor, rigidity and shuffling gait. Other competing pharmaceutical products, including dopamine agonists and products having different mechanisms of action, have also been approved for treatment of the symptoms of Parkinson’s disease.
Field of Use
The rights granted apply to the drug market relating to the pharmaceutical healthcare industry.

IPSCIO Record ID: 27665

License Grant
For Research and Development, Licensor grants an exclusive sublicense, with the right to grant further sublicenses, under Licensed Know-How and Licensed Patent Rights to research, develop, import, make, have made and use Licensed Products in the Field in the Territory.

For Commercialization, Licensor grants an exclusive license, with the right to grant sublicenses, under Licensed Know-How and Licensed Patent Rights to make, have made, use, import, offer for sale and sell Licensed Products in the Field in the Territory.

License Property
Licensor has licensed, owns or controls patents and know-how relating to [123I]-E-IACFT Injection.

The product name is ALTROPANE.  Licensed Product means a pharmaceutical product, whether prescription or over-the-counter, for use in the Field containing [123I]-E-IACFT Injection.

Altropane is an iodine-123 radiolabeled imaging agent which is being developed as an aid in the diagnosis of Parkinson’s disease and movement disorders. Altropane and is a molecular imaging program focused on the diagnosis of i) Parkinsonian Syndromes, or PS, including Parkinson’s Disease, or PD, and ii) Dementia with Lewy Bodies, or DLB.

Field of Use
The Field means all uses in humans.  The product is an Iodine-123 radiolabeled imaging agent being developed as an aid in the diagnosis of Parkinson’s disease and other movement disorders.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.